TSX News -
IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac’s Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018
IMV to host an investor call on Thursday, December 13 at 8:30 a.m. ET to discuss the presentation DARTMOUTH, Nova […]